Crescent Biopharma
CBIO
82 hedge funds and large institutions have $533M invested in Crescent Biopharma in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 12 closing their positions.
158% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 12
30% more funds holding
Funds holding: 63 → 82 (+19)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
13.14% more ownership
Funds ownership: 94.17% → 107.31% (+13%)
12% more capital invested
Capital invested by funds: $477M → $533M (+$55.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$27.7M |
| 2 |
BlackRock
New York
|
+$22.6M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.91M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.47M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.33M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.85M |
| 3 |
Goldman Sachs
New York
|
-$4.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.92M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.63M |
CBIO Hedge Fund Activity: Q2 2026 in Review
82 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2026, worth a combined $533M — up 12% from $477M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CBIO positions and 12 closed out — a net gain of 19 holders — while 17 added to existing stakes and 15 trimmed.
The largest buyer was Logos Global Management, adding an estimated $27.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $8.33M sold.
- 82 institutional investors held Crescent Biopharma (CBIO) as of Q2 2026, up from 63 in Q1 2026.
- Funds reported $533M of Crescent Biopharma stock for Q2 2026, up 12% quarter-over-quarter.
- 31 funds opened new Crescent Biopharma positions in Q2 2026 and 12 closed out, a net change of +19 holders.
- The largest Crescent Biopharma buyer in Q2 2026 was Logos Global Management, an estimated $27.7M added.
- The largest Crescent Biopharma seller in Q2 2026 was Deep Track Capital, an estimated $8.33M sold.
Based on aggregated 13F filings for Q2 2026.